Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review Supplementary materials

M Heuser: Research funding: Abbvie, Astellas, BergenBio, BMS, Bayer Pharma AG, Daiichi Sankyo, Jazz Pharmaceuticals, Karyopharm, Novartis, Pfizer, PinotBio, Roche; Honoraria: Abbvie, Jazz Pharmaceuticals, Janssen, Novartis; Consulting: Abbvie, BMS, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, PinotBio, Roche, Tolremo. C Fernandez is an employee of Servier. O Hauch is a consultant for Servier. OM Klibanov is an employee of IQVIA. T Chaudhary is an employee of IQVIA. V Rives is an employee of Servier. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support was provided by L Huber and R Kurtkoti of IQVIA, which was funded by Servier, Suresnes, France, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).